• About
    • Who We Are
    • Leadership Team
    • Board of Directors
    • Clinical and Scientific Advisors
    • Contact
  • Science
    • Immune Continuum
    • CCR4 in Cancer
    • CCR4 in Inflammation
    • GCN2
    • Publications
  • Pipeline
    • Snapshot
    • FLX475
    • RPT193
    • GCN2i
    • HPK1
    • Discovery Programs
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Email Alerts
    • Investor Contact
    • Investor FAQs
  • Careers
    • Culture
    • Benefits
    • Open Positions

PRESS RELEASES

Year
February 19 | 2021
RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
January 05 | 2021
RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
November 23 | 2020
RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 16 | 2020
RAPT Therapeutics Reports Third Quarter 2020 Financial Results
November 16 | 2020
RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
November 15 | 2020
RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
November 13 | 2020
RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
October 14 | 2020
RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D., to Scientific Advisory Board
September 03 | 2020
RAPT Therapeutics to Present at Upcoming Virtual Investor Conferences
August 13 | 2020
RAPT Therapeutics Reports Second Quarter 2020 Financial Results
Contact Us
+1.650.489.9000
inquiries@rapt.com
  • Home
  • About
  • Science
  • Pipeline
  • Investors & Media
  • Careers
  • Terms Of Use
  • Privacy Policy

RAPT Therapeutics
561 Eccles Avenue
South San Francisco, CA 94080
Tel: +1 650 489 9000
Email: inquiries@rapt.com

RAPT Therapeutics, formerly known as FLX Bio.

© 2021 RAPT Therapeutics. All right reserved.